On Monday, Guardant Health hit an important technical milestone, with its Relative Strength (RS) Rating climbing into the 90-plus percentile with an improvement to 91, a rise from 87 the day before.
How To Use Stock Charts To Stay Profitable And Protected
This proprietary rating measures technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks matches up against all other stocks in our database.
Decades of market research reveals that the best-performing stocks typically have an RS Rating north of 80 at the beginning of a new price run.
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to form a base and break out.
Guardant Health reported 0% EPS growth in its most recent report. Sales increased 21%.
Guardant Health holds the No. 15 rank among its peers in the Medical-Services industry group. Hims & Hers Health, Option Care Health and GeneDx Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
